Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

Priovant Therapeutics, Inc. · NCT06978725

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
168
US sites recruiting
39
Study start
April 9, 2025
Record last updated
October 21, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Being studied: Oral Brepocitinib; Oral Placebo

Conditions: Cutaneous Sarcoidosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Adults subjects
  • Cutaneous sarcoidosis with characteristic skin biopsy histology
  • A CSAMI activity score ≥ 10
  • Weight > 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.

Exclusion Criteria

  • History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
  • High risk of thrombosis or cardiovascular disease
  • High risk of herpes zoster
  • Active or recent infection

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trial Administrator · (212) 634-9743 · clinicaltrials@priovant.com